Immunogen Inc was incorporated in 1981, in Massachusetts. The Company is a biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products. The Company develops its own product candidates using its ADC technology. It has three wholly owned, clinical-stage anticancer compounds: IMGN853, IMGN289, and IMGN529. It's IMGN853 product candidate is used for the treatment of ovarian cancer, endometrial cancer, and potentially other cancers that highly express folate receptor a, or FRa. It's EGFR-targeting ADC, IMGN289, is used for the treatment of cancers that highly express EGFR which include squamous cell carcinoma of the head and neck, or SCCHN, and types of non-small cell lung cancer (NSCLC), including both squamous cell and non-squamous cell NSCLCs. It's IMGN529 ADC is used for the treatment of cancers that highly express CD37, such as non-Hodgkin lymphoma, or NHL, and chronic lymphocytic leukemia. The Company's main competitors include Pfizer, Seattle Genetics, Roche and Bristol-Myers Squibb. In addition to regulations in the U.S., the company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products.